x

Search for a clinical trial

* (*) mandatory field

CENTRIC: A Multicenter, open-label, controlled Phase III Study, assessing efficacy and safety of Cilengitide in combination with standard treatment (Temozolomide with concomitant radiation therapy, followed by Temozolomide maintenance therapy) versus standard treatment alone for patients with newly diagnosed Glioblastoma Multiforme and methylated MGMT gene promoter - DE

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Terminated trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Merck kgaa
  • Website
  • Principal investigator of clinical trial

  • Pr Ulrich HERRLINGER
  • Klinik und Poliklinik für Neurologie
  • Universitätsklinikum Bonn
  • Sigmund-Freud-Str. 25
  • 53105 BONN
  • GERMANY
  • More information
  • Phone  : 49 (0)228 287 15750
  • Fax  : 49 (0)228 287 15024
  • Website
  • Contact secretary  :
  • Sponsor of clinical trial

  • MERCK KGAA
  • Merck KGaA
  • Franfurter Strasse 250
  • 64293 DARMSTADT
  • GERMANY
  • More information
  • Phone  : 49 (0)6151 72 0
  • Fax  : 49 (0)6151 72 2000
  • Website
  • Contact secretary  :
Last update: August 2016

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.